EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

How and what adverse events are reported and captured in randomized control trials of emollients in the treatment of eczema?

Elizabeth R Emmett iD, Megan Allen, Sarah Crownshaw, Matthew J Ridd

Clinical and Experimental Dermatology · 2023

DOI: 10.1093/ced/llad137 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2023. Verfasst von Elizabeth R Emmett und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gloucestershire NHS Trust, Cheltenham, UK. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Eczema. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academy of Medical Sciences, INSPIRE, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Emollients are universally recommended for atopic dermatitis/eczema (‘eczema’), to improve the skin barrier and reduce symptoms. However, our knowledge of the frequency and nature of adverse effects associated with their use is limited.

Objectives

We sought to determine how well adverse events are reported in randomized controlled trials (RCTs) of emollients for eczema.

Methods

MEDLINE was searched from inception (1946) to May 2022. Inclusion criteria were RCTs of moisturizers or emollients used as a leave-on treatment (as the intervention or control) in adults or children with eczema. Exclusion criteria were non-RCTs; patients with other diagnoses included; use of emollient as bath additives, soap substitutes or as preventative; and not published in English. References of eligible papers were reviewed for any additional, relevant research. Data were extracted into an Excel spreadsheet and analysed descriptively. An assessment of study quality was carried out using the Joanna Briggs Institute tool for RCTs.

Results

From 369 potential papers, 35 papers (reporting on 34 studies) were included. Most research was conducted in research centres or hospitals (unclear in 34%). In total, 89% reported collecting data on adverse events related to emollient treatment use but the methods used were poorly reported (40% unclear). Four papers used patient questionnaires/diaries. However, it was unclear how and what was collected as only two studies showed the questionnaires used.

Conclusions

Reporting of adverse events related to emollient use in trials of patients with eczema is poor and inconsistent. Agreement should be reached on how and what adverse events should be collected, to standardize reporting across studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicEczemaAdultChildHumansEmollientsResearch DesignRandomized Controlled Trials as Topic

Substanzen

Emollients

Autor:innen und Institutionen

  • Gloucestershire NHS Trust, Cheltenham, UK.
  • Bristol Medical School, University of Bristol, Bristol, UK.
  • Great Western Hospitals NHS Trust, Swindon, UK.

ORCID-Profile: Elizabeth R Emmett

Förderung

  • Academy of Medical Sciences
  • INSPIRE
  • Wellcome Trust

Zitieren

APA

Emmett, E. R., Allen, M., Crownshaw, S., & Ridd, M. J. (2023). How and what adverse events are reported and captured in randomized control trials of emollients in the treatment of eczema?. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad137

Vancouver

Emmett ER, Allen M, Crownshaw S, Ridd MJ. How and what adverse events are reported and captured in randomized control trials of emollients in the treatment of eczema?. Clinical and Experimental Dermatology. 2023. doi:10.1093/ced/llad137

BibTeX
@article{Emmett2023,
  author = {Emmett, Elizabeth R and Allen, Megan and Crownshaw, Sarah and Ridd, Matthew J},
  title = {How and what adverse events are reported and captured in randomized control trials of emollients in the treatment of eczema?},
  journal = {Clinical and Experimental Dermatology},
  year = {2023},
  doi = {10.1093/ced/llad137}
}
Kostenlos starten →